

OPEN

Author Correction: Early Cellular Responses of Prostate Carcinoma Cells to Sepantronium Bromide (YM155) Involve Suppression of mTORC1 by AMPK

David Danielpour^{1,2,3}, Zhaofeng Gao⁷, Patrick M. Zmina¹, Eswar Shankar¹, Benjamin C. Shultes^{1,4}, Raul Jobava⁷, Scott M. Welford^{5,6} & Maria Hatzoglou⁷

Correction to: *Scientific Reports* <https://doi.org/10.1038/s41598-019-47573-y>, published online 08 August 2019

In Figure 9A, the connection between S6K1 and Rictor was switched with that between Rictor and mTORC2. The correct Figure 9 appears below as Figure 1.

¹Case Comprehensive Cancer Center Research Laboratories, The Division of General Medical Sciences-Oncology, Case Western Reserve University, Cleveland, OH, 44106, USA. ²Department of Pharmacology, Case Western Reserve University, Cleveland, OH, 44106, USA. ³Department of Urology, University Hospitals of Cleveland, Cleveland, OH, 44106, USA. ⁴Department of Biochemistry, Case Western Reserve University, Cleveland, OH, 44106, USA. ⁵Department of Radiation Oncology, Case Western Reserve University, Cleveland, OH, 44106, USA. ⁶Department of Radiation Oncology, University of Miami, Coral Gables, FL, 33136, USA. ⁷Department of Genetics and Genomic Sciences, Case Western Reserve University, Cleveland, OH, 44106, USA. Zhaofeng Gao, Patrick M. Zmina and Eswar Shankar contributed equally. Correspondence and requests for materials should be addressed to D.D. (email: dxd49@case.edu)




Figure 1. Summary of our model on the molecular action of YM155 in prostate cancer cells. Panel A represents the overall molecular steps in which our model supports that YM155 rapidly promotes the activation of AMPK and subsequent inactivation of mTORC1 and suppression of cap-dependent translation of proteins involved in cell cycle and survival. This model also illustrates that YM155 additionally promotes the loss of AMPK α 1 or AMPK α 2, and that such loss counter-intuitively promotes growth arrest and cell death. Panel B is a simplified version of panel A.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019